Published in J Virol on March 01, 2002
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A (2002) 11.11
Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol (2003) 3.29
Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol (2003) 2.67
Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution x-ray crystallographic, molecular modeling, and sequence-based methods. J Virol (2003) 2.10
Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol (2005) 2.05
Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev (2011) 2.04
Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol (2010) 1.96
Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol (2004) 1.86
Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. J Virol (2004) 1.66
Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol (2003) 1.60
Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae. J Virol (2010) 1.58
Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice. J Clin Invest (2007) 1.57
Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J Virol (2004) 1.53
Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A. J Virol (2008) 1.52
Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol (2003) 1.48
Current strategies and future directions for eluding adenoviral vector immunity. Curr Gene Ther (2006) 1.42
Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther (2011) 1.42
Multiple immunizations with adenovirus and MVA vectors improve CD8+ T cell functionality and mucosal homing. Virology (2007) 1.26
Development of nonhuman adenoviruses as vaccine vectors. Vaccine (2005) 1.25
Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine (2009) 1.24
Respiratory syncytial virus vaccine development. Expert Rev Vaccines (2011) 1.18
The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus. J Immunol (2011) 1.17
Structure-based identification of a major neutralizing site in an adenovirus hexon. J Virol (2006) 1.17
Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity. Infect Immun (2005) 1.13
Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther (2011) 1.07
An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector. Nat Protoc (2010) 1.07
Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity. Vaccine (2009) 1.07
A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses. Immunol Lett (2008) 1.02
Novel vaccines to human rabies. PLoS Negl Trop Dis (2009) 1.02
Frequency, proliferation, and activation of human memory T cells induced by a nonhuman adenovirus. J Virol (2005) 1.00
An update on canine adenovirus type 2 and its vectors. Viruses (2010) 1.00
Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling. J Clin Invest (2015) 0.99
Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo. J Virol (2009) 0.99
Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business". J Virol (2007) 0.96
The influence of delivery vectors on HIV vaccine efficacy. Front Microbiol (2014) 0.92
Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation. Mol Ther (2013) 0.91
Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28. Vaccine (2010) 0.91
Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1. Vaccine (2006) 0.90
Advances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccines. Viruses (2012) 0.89
T cells induced by recombinant chimpanzee adenovirus alone and in prime-boost regimens decrease chimeric EcoHIV/NDK challenge virus load. Eur J Immunol (2012) 0.88
Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF. Vaccine (2011) 0.88
Robust genital gag-specific CD8+ T-cell responses in mice upon intramuscular immunization with simian adenoviral vectors expressing HIV-1-gag. Eur J Immunol (2010) 0.86
Prospects for oral replicating adenovirus-vectored vaccines. Vaccine (2013) 0.86
Neutralizing antibody responses to enterovirus and adenovirus in healthy adults in China. Emerg Microbes Infect (2014) 0.84
Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses. PLoS One (2012) 0.83
Genetic medicine strategies to protect against bioterrorism. Trans Am Clin Climatol Assoc (2006) 0.83
Vaccine-induced T cells provide partial protection against high-dose rectal SIVmac239 challenge of rhesus macaques. Mol Ther (2010) 0.82
Hexon-modified recombinant E1-deleted adenovirus vectors as dual specificity vaccine carriers for influenza virus. Mol Ther (2012) 0.81
Protection of non-human primates against rabies with an adenovirus recombinant vaccine. Virology (2014) 0.80
Circumventing antivector immunity: potential use of nonhuman adenoviral vectors. Hum Gene Ther (2014) 0.79
Influenza virus specific CD8⁺ T cells exacerbate infection following high dose influenza challenge of aged mice. Biomed Res Int (2013) 0.78
The effect of adenovirus-specific antibodies on adenoviral vector-induced, transgene product-specific T cell responses. J Leukoc Biol (2014) 0.76
Induction of complex immune responses and strong protection against retrovirus challenge by adenovirus-based immunization depends on the order of vaccine delivery. Retrovirology (2017) 0.76
Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal. PLoS One (2016) 0.75
A novel oncolytic adenovirus based on simian adenovirus serotype 24. Oncotarget (2017) 0.75
Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol (1977) 41.93
Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science (1997) 14.41
Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell (1993) 13.21
Development of a preventive vaccine for Ebola virus infection in primates. Nature (2000) 8.32
Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther (1999) 4.65
Replication-defective vector based on a chimpanzee adenovirus. J Virol (2001) 2.86
Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther (1996) 2.43
A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology (1996) 2.35
Adenoviruses as gene-delivery vehicles. N Engl J Med (1996) 2.20
Antigen sampling across epithelial barriers and induction of mucosal immune responses. Annu Rev Immunol (1996) 2.11
Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria. J Immunol (1997) 1.80
Characterization of four new adenovirus serotypes isolated from chimpanzee tissue explants. Am J Epidemiol (1971) 1.61
Prevalence of antibodies to adenovirus serotypes 4 and 7 among unimmunized US Army trainees: results of a retrospective nationwide seroprevalence survey. J Infect Dis (1998) 1.48
Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology (2000) 1.44
Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo. J Virol (1999) 1.40
Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor. J Gen Virol (2002) 1.38
Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy. Virology (2000) 1.30
Adult dogs receiving a rabies booster dose with a recombinant adenovirus expressing rabies virus glycoprotein develop high titers of neutralizing antibodies. Vaccine (2000) 1.15
Induction of genital immunity by DNA priming and intranasal booster immunization with a replication-defective adenoviral recombinant. J Immunol (1999) 1.04
The common mucosal immune system: from basic principles to enteric vaccines with relevance for the female reproductive tract. Reprod Fertil Dev (1994) 0.98
Immune effector mechanisms required for protection to rabies virus. Virology (1995) 0.98
Presentation of SIVgag to monkey T cells using dendritic cells transfected with a recombinant adenovirus. Eur J Immunol (2000) 0.95
Adenovirus vectored vaccines. Dev Biol Stand (1994) 0.92
Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16. Vaccine (2001) 0.92
Induction of humoral and cellular immune responses against the nucleocapsid of bovine viral diarrhea virus by an adenovirus vector with an inducible promoter. Virology (1999) 0.83
Recombinant adenovirus gene transfer in adults with partial ornithine transcarbamylase deficiency (OTCD). Hum Gene Ther (1999) 0.82
A simple method to test the ability of individual viral proteins to induce immune responses. J Virol Methods (1994) 0.82
Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature (2012) 18.23
The Genome sequence of the SARS-associated coronavirus. Science (2003) 16.68
Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA (2003) 16.08
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A (2002) 11.11
Genome-wide association study of 107 phenotypes in Arabidopsis thaliana inbred lines. Nature (2010) 10.66
Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature (2007) 10.40
Modelling schizophrenia using human induced pluripotent stem cells. Nature (2011) 7.41
Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A (2008) 7.16
Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol (2004) 7.12
A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci U S A (2012) 6.27
Trends in survival after in-hospital cardiac arrest. N Engl J Med (2012) 5.67
Characterization of human metapneumoviruses isolated from patients in North America. J Infect Dis (2002) 5.64
Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med (2003) 5.45
Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab (2003) 5.27
CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med (2007) 5.24
Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet (2007) 5.21
A high-resolution map of the three-dimensional chromatin interactome in human cells. Nature (2013) 5.18
Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation. Science (2006) 4.71
Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell (2006) 4.68
Human illness from avian influenza H7N3, British Columbia. Emerg Infect Dis (2004) 4.29
Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis (2009) 4.27
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol (2011) 4.16
New world bats harbor diverse influenza A viruses. PLoS Pathog (2013) 4.10
Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol (2013) 3.90
Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell (2005) 3.89
New recombinant serotypes of AAV vectors. Curr Gene Ther (2005) 3.87
Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada. PLoS Med (2010) 3.85
Long-term outcomes in elderly survivors of in-hospital cardiac arrest. N Engl J Med (2013) 3.85
Epigenomic analysis of multilineage differentiation of human embryonic stem cells. Cell (2013) 3.81
Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci U S A (2009) 3.58
Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol (2007) 3.54
Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol (2003) 3.51
Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. J Am Coll Cardiol (2004) 3.49
Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol (2010) 3.49
AMPylation of Rho GTPases by Vibrio VopS disrupts effector binding and downstream signaling. Science (2008) 3.44
Ambulatory arterial stiffness index as a predictor of cardiovascular mortality in the Dublin Outcome Study. Hypertension (2006) 3.42
Coxsackievirus entry across epithelial tight junctions requires occludin and the small GTPases Rab34 and Rab5. Cell Host Microbe (2007) 3.34
Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc Natl Acad Sci U S A (2003) 3.31
Human Bocavirus infection, Canada. Emerg Infect Dis (2006) 3.30
Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. Mol Ther (2007) 3.26
Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature (2004) 3.24
A Pseudomonas syringae effector inactivates MAPKs to suppress PAMP-induced immunity in plants. Cell Host Microbe (2007) 3.15
The scale of population structure in Arabidopsis thaliana. PLoS Genet (2010) 3.12
PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. J Cell Biol (2014) 3.12
Adenoviruses as vaccine vectors. Mol Ther (2004) 3.09
Triple reassortant H3N2 influenza A viruses, Canada, 2005. Emerg Infect Dis (2006) 3.05
Label-free, normalized quantification of complex mass spectrometry data for proteomic analysis. Nat Biotechnol (2009) 3.01
Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature (2013) 3.00
Identification of a novel astrovirus (astrovirus VA1) associated with an outbreak of acute gastroenteritis. J Virol (2009) 2.96
Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol (2012) 2.91
Novel avian influenza H7N3 strain outbreak, British Columbia. Emerg Infect Dis (2004) 2.90
Masked hypertension in diabetes mellitus: treatment implications for clinical practice. Hypertension (2013) 2.89
A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol (2003) 2.85
Pseudomonas syringae effector AvrPto blocks innate immunity by targeting receptor kinases. Curr Biol (2007) 2.84
Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow. Cell (2008) 2.84
Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. Nat Med (2006) 2.78
Anterior chamber width measurement by high-speed optical coherence tomography. Ophthalmology (2005) 2.77
Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results. Hum Gene Ther (2011) 2.75
Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat Med (2013) 2.70
Susceptibility to neurodegeneration in a glaucoma is modified by Bax gene dosage. PLoS Genet (2005) 2.68
Progressive ganglion cell loss and optic nerve degeneration in DBA/2J mice is variable and asymmetric. BMC Neurosci (2006) 2.68
Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum Gene Ther (2007) 2.64
Prognostic value of reading-to-reading blood pressure variability over 24 hours in 8938 subjects from 11 populations. Hypertension (2010) 2.64
Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med (2010) 2.62
Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. Proc Natl Acad Sci U S A (2008) 2.62
Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study. Lancet Neurol (2010) 2.60
Transcriptome characterization elucidates signaling networks that control human ES cell growth and differentiation. Nat Biotechnol (2004) 2.60
Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. J Infect Dis (2009) 2.59
Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Hum Gene Ther (2010) 2.51
A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol (2003) 2.50
Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ (2011) 2.50
Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol (2011) 2.50
Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. Mol Ther (2005) 2.48
miR-301a as an NF-κB activator in pancreatic cancer cells. EMBO J (2010) 2.47
A coastal cline in sodium accumulation in Arabidopsis thaliana is driven by natural variation of the sodium transporter AtHKT1;1. PLoS Genet (2010) 2.45
Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview. Hypertension (2007) 2.43
Random migration precedes stable target cell interactions of tumor-infiltrating T cells. J Exp Med (2006) 2.43
Two calcium-dependent protein kinases, CPK4 and CPK11, regulate abscisic acid signal transduction in Arabidopsis. Plant Cell (2007) 2.40
Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med (2002) 2.38
Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med (2002) 2.37
Genome sequencing and comparison of two nonhuman primate animal models, the cynomolgus and Chinese rhesus macaques. Nat Biotechnol (2011) 2.37
Ambulatory blood pressure monitoring in 9357 subjects from 11 populations highlights missed opportunities for cardiovascular prevention in women. Hypertension (2011) 2.33
beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. Cancer Cell (2002) 2.33
Pathogenesis of avian influenza (H7) virus infection in mice and ferrets: enhanced virulence of Eurasian H7N7 viruses isolated from humans. J Virol (2007) 2.30
Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens (2010) 2.28
A transforming metal nanocomposite with large elastic strain, low modulus, and high strength. Science (2013) 2.28
Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther (2008) 2.27
A cross-sectional study of the microeconomic impact of cardiovascular disease hospitalization in four low- and middle-income countries. PLoS One (2011) 2.23
Positional cloning of the murine flavivirus resistance gene. Proc Natl Acad Sci U S A (2002) 2.22
Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. Blood (2003) 2.21
Human cone photoreceptor dependence on RPE65 isomerase. Proc Natl Acad Sci U S A (2007) 2.21
Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood (2007) 2.21